CAMP Continuation Study/Phse 2 (CAMPCS/2)

要检验的主要假设是，3.5-5年使用吸入皮质类固醇治疗5-12岁儿童哮喘是否在允许最大限度地实现肺生长方面有长期好处。这将通过继续跟进最初的儿童哮喘管理计划(CAMP)队列来实现，直到大多数人达到他们成年后的最大身高。阿尔伯克基站点同意继续跟踪并获得他们队列中的必要测量结果，以实现华盛顿大学圣路易斯分校科学协议中描述的所有特定目标。121名患者最初在阿尔伯克基进行了随机抽样，目前我们有100名患者登记在CAMPCS队列中 随访研究。在目前在CAMPCS登记的患者中，截至2002年8月，我们成功地完成了96%的所有肺功能测量，97%的线性增长测量和93%的乙酰胆碱挑战测量。最初的队列包括41%的少数族裔和40%的女性，他们都有资格参加，我们将尝试联系他们，即使是那些目前没有加入CAMPCS的人。

The primary hypothesis to be tested is whether 3.5-5 years treatment of asthma in children 5-12 years of age with inhaled corticosteroids has a long-term benefit in allowing maximum attainment of lung growth. This will be achieved by continued followup of the original Childhood Asthma Management Program (CAMP) cohort until the majority have reached their maximal adult height. The Albuquerque site agrees to continue to follow and obtain the necessary measurements in their cohort to fulfill all of the specific aims as described in the Washington University, St. Louis scientific protocol. One hundred twenty-one patients were initially randomized at the Albuquerque site and we currently have 100 patients enrolled in the CAMPCS cohort followup study. Of those patients currently enrolled in CAMPCS we have successfully completed 96% of all pulmonary function measures, 97% of all linear growth measures and 93% of all methacholine challenge measures up to August 2002. All of the original cohort which consisted of 41% minorities and 40% females is eligible to participate and we will attempt to contact them all, even those not currently enrolled in CAMPCS.